Skip to main content
Academic Programs Chemical Biology and Medicinal Chemistry Divisions PhD Pharmacoengineering and Molecular Pharmaceutics Research Students,
Grayson Mendenhall
June 30, 2014



Sarah Claypool
CBMC’s Sarah Claypool takes the stage for a poster presentation at West Virginia University.
  • Two graduate students won awards for their research at WVU’s pharmacy research forum on June 12–13.
  • MOPH’s Chintan Kapadia placed first in the podium presentations, and CBMC’s Sarah Claypool placed third in the poster presentations.

Two UNC Eshelman School of Pharmacy graduate students received awards at the inaugural West Virginia University School of Pharmacy Regional Research Forum.

About 100 participants from academia and industry attended the two-day conference, which took place on June 12–13. Those in attendance participated in communications workshops, podium and poster presentations, and career panel discussions.

Podium and poster presentations were divided into two categories: health outcomes and pharmaceutical sciences. Sarah Claypool and Chintan Kapadia each presented their research in the pharmaceutical sciences category.

Kapadia Takes First in Podium Presentation

Chintan Kapadia
MOPH’s Chintan Kapadia discusses particle-based vaccines in the treatment of cancer at West Virginia University.

Kapadia, a graduate student in the Division of Molecular Pharmaceutics, presented his research on cancer immunotherapy.

In his presentation, he discussed the development of particle-based vaccines in the treatment of cancer. The study found ‘antigen-specific cytotoxic T cells to be more responsive to PRINT nanoparticulate vaccines than free antigen vaccines.

The panel of judges awarded Kapadia first place for his podium presentation. His faculty adviser is Joe Desimone, PhD.

Claypool Takes Third in Poster Presentation

Claypool, a graduate student in the Division of Chemical Biology and Medicinal Chemistry, presented her research on the treatment of pancreatic ductal adenocarcinoma.

PDAC has a five-year survival rate of 6 percent. In her presentation, Claypool discussed the development of an RNA aptamer that binds only to the biomarkers of cancerous cells in the pancreas. The study proposes that by avoiding normal pancreatic cells and nonpancreatic cells, PDAC may be treated more effectively.

A panel of judges awarded Claypool third place for her poster presentation. Her faculty adviser is Rihe Liu, PhD.

By Abigal Brewer

Latest News


Comments are closed.